GEN News Highlights

Biosearch Moving into New Digs for GMP Production

(Page
1
of
1)

Biosearch Technologies, a company that specializes in the development and manufacture of GMP-grade oligonucleotides, is moving its GMP manufacturing process into a new GMP production facility in Novato, CA, which is also the home of Biosearch's headquarters. The 30,000 square foot facility was developed to further expand processes and controls relevant to medical device and molecular diagnostic customers.

“The GMP production facility is designed to incorporate the environmental and access controls, linear production flow, and clean room processes critical for the controlled manufacture of highly qualified diagnostic components, reagents, and kits,” said Ron Cook, president and CEO of Biosearch Technologies. “This advanced facility also introduces pharmaceutical-scale lyophilization capabilities allowing for state-of-the-art processing of molecular diagnostic assays in large-scale single batches and all format types.”

In addition to the relocation to the new facility, Biosearch says it has also successfully completed certification to ISO 13485:2003, meaning that Biosearch has developed, implemented, and maintains a quality management system able to meet the requirements of medical device and molecular diagnostic manufacturing. ISO 13485:2003, according to ISO's website, “specifies requirements for a quality management system where an organization needs to demonstrate its ability to provide medical devices and related services that consistently meet customer requirements and regulatory requirements applicable to medical devices and related services.”

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

GEN Poll

Secure Science

Should bans on science education, of the sort imposed on Iranians hoping to study physics and engineering in the United States, encompass other nationals and other fields of study, including biotechnology?

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

56.6%

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.